Good morning, Boston. This is Digital Editor Jess Aloe bringing you the five things you need to know in Boston business news to start your Friday.
The U.S. Food and Drug Administration granted full, traditional approval to an Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. late Thursday afternoon, six months after it won conditional approval from the same agency. Rowan Walrath brings you details on what that means for patients and the company.
Professional services giant Deloitte…
